Limbach Acquires Pioneer Power
Founded in 1947 and formerly 100% ESOP-owned, PPI is a provider of industrial and institutional mechanical solutions serving healthcare, food, power/utility, oil refining and other select end markets in the Greater Twin Cities region and the Upper Midwest. PPI serves owners of mission critical facilities and leverages exceptional industrial piping, HVAC, and plumbing capabilities to execute complex facility shutdowns and turnarounds, capital projects, facility expansions, renovation and retrofit opportunities, and reoccurring industrial maintenance services.
Limbach expects an incremental impact on revenue and adjusted EBITDA in 2025 and anticipates providing an updated outlook for fiscal 2025 when it reports second quarter 2025 results in August. PPI is currently expected to contribute annualized revenue and adjusted EBITDA of approximately $120 million and $10 million, respectively, beginning in 2026. The Company's primary focus will be on further integrating operations and unlocking synergies in 2026.
The purchase price is subject to customary working capital adjustments and includes owned real property associated with PPI's headquarters, warehouse, and fabrication facility valued at approximately $4.6 million. In conjunction with the transaction, Limbach entered into an amendment to its credit agreement with its lender, Wheaton Bank & Trust Company, N.A., a subsidiary of Wintrust Financial Corporation, to expand the size of its revolving credit facility from $50 million to $100 million and make other conforming changes to the credit facility.
Management Commentary
'We are excited to welcome the Pioneer Power team to the Limbach family,' said Michael McCann, President and Chief Executive Officer of Limbach. "This acquisition further expands our footprint in the core Midwest region and extends our reach into new geographic markets in the Upper Midwest. Since Pioneer Power generates the majority of its revenue through Owner Direct Relationships ('ODR'), primarily through time and materials contracts and small capital project work focused on maintenance, renovation and retrofit activity, it aligns well with our strategic shift towards prioritizing ODR. Its industrial expertise builds on the capabilities acquired in our recent acquisition of Consolidated Mechanical and brings many new blue-chip customers with extensive and diverse mechanical system needs in large facilities. Our immediate focus will be on integrating operations and unlocking value by applying our proven value creation strategies to grow market share among core customers, improve gross margins over time, and deepen customer relationships as a trusted provider of mission-critical mechanical services.
'With this transaction, Limbach has paid more than $150 million in total consideration for strategic acquisitions since becoming public, all without issuing any stock as consideration. We've managed to grow aggressively while preserving stockholder value—financing acquisitions through disciplined cash flow management and targeted use of our balance sheet. Through this prudent financial management, we have maintained significant financial flexibility and low leverage, and we remain well positioned to continue to support organic and acquisition-driven growth initiatives.
'I want to thank the Pioneer Power leadership team, its ESOP shareholders, and its skilled tradespeople for building a highly regarded and capable organization. We appreciate their highly compatible culture and approach to risk management, and commitment to optimizing customers' facilities through value-enhancing mechanical system solutions,' concluded McCann.
Larry Stevens, Jr., Pioneer Power's President, added, 'The combination of Pioneer Power into Limbach will provide our customers, employees and other stakeholders access to considerable resources to better serve their needs. We are excited to be part of the Limbach organization and look forward to further extending our industrial presence in the Upper Midwest market.'
About Limbach
Limbach is a building systems solutions firm that partners with building owners and facilities managers who have mission-critical mechanical (heating, ventilation, and air conditioning), electrical and plumbing infrastructure. We strive to be an indispensable partner to our customers by providing services that are essential to the operation of their businesses. We work with building owners primarily in six vertical markets: healthcare, industrial and manufacturing, data centers, life science, higher education, and cultural and entertainment. We have approximately 1,600 team members in 21 offices across the eastern United States. Our team members uniquely combine engineering expertise with field installation skills to provide custom solutions that leverage our full life-cycle capabilities, which allows us to address both the operational and capital projects needs of our customers.
About Pioneer Power
Pioneer Power is a full-service mechanical contractor headquartered in the Twin Cities, serving the Upper Midwest since 1947. It specializes in pipe fabrication and installation, HVAC, plumbing, sheet metal, mechanical maintenance, and project management. Pioneer Power supports critical infrastructure across key markets, including healthcare, manufacturing, energy, food and beverage, data centers, water and wastewater, and government. Known for its commitment to safety, quality, and reliability, Pioneer Power delivers complex mechanical solutions. More information can be found at www.pioneerpower.com.
Forward-Looking Statements
We make forward-looking statements in this press release within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events, including, without limitation, our earnings, Adjusted EBITDA, projected revenues and EBITDA production from acquisitions, including from Pioneer Power, revenues, expenses, backlog, capital expenditures or other future financial or business performance or strategies, results of operations or financial condition, timing of the recognition of backlog as revenue, the potential for recovery of cost overruns, and the ability of Limbach to successfully remedy the issues that have led to write-downs in various business units and the Company's business being negatively affected by the health crises or outbreaks of diseases, such as epidemics or pandemics (and related impacts, such as supply chain disruptions). These statements may be preceded by, followed by or include the words 'may,' 'might,' 'will,' 'will likely result,' 'should,' 'estimate,' 'plan,' 'project,' 'forecast,' 'intend,' 'expect,' 'anticipate,' 'believe,' 'seek,' 'continue,' 'target,' 'goal,' or similar expressions. These forward-looking statements are based on information available to us as of the date they were made and involve a number of risks and uncertainties, which may cause them to turn out to be wrong. There may be additional risks that we consider immaterial or which are unknown. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Please refer to our most recent annual report on Form 10-K, as well as our subsequent filings on Form 10-Q and Form 8-K, which are available on the SEC's website (www.sec.gov), for a full discussion of the risks and other factors that may impact any forward-looking statements in this press release.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
44 minutes ago
- Associated Press
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona (abstract #388MO) . Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. I-Mab plans to host a virtual investor event on Tuesday, July 8th (register here ) to review these data. The Phase 1b data (NCT04900818) show a confirmed objective response rate (ORR) of 71% across all doses (12/17), and 83% (10/12) at doses selected for the ongoing dose expansion study (8 mg/kg and 12 mg/kg). Responses occurred in tumors with low levels of PD-L1 expression and/or Claudin 18.2 (CLDN18.2) expression, with favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 TRAE for increased liver enzymes. The data are based on the results of the dose escalation part of a Phase 1b study evaluating the givastomig combination as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (≥1+ IHC staining intensity in ≥1% of tumor cells). The primary endpoint is safety. The study enrolled only patients in the U.S. 'The positive Phase 1b combination data presented at ESMO GI bolster our confidence in givastomig's potential to be a best-in-class Claudin 18.2 directed therapy. Givastomig has been well tolerated when combined with immuno-oncology and chemotherapy, has shown a high objective response rate, with rapid onset and durable responses that have deepened over time, supported by consistent pharmacokinetic data and soluble 4-1BB induction,' said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab. 'In addition, we are optimistic about the results from the 8 mg/kg and 12 mg/kg doses. These doses showed an ORR of 83%, with consistent responses across PD-L1 and Claudin 18.2 expression levels, and a favorable overall safety profile. These data further our conviction in the ongoing Phase 1b dose expansion study. We believe givastomig has broad potential in a number of gastric cancer settings and look forward to continued advancement of the program.' 'I am encouraged by the response rates, as well as the deepening of responses over time, demonstrated by the givastomig combination regimen in the Phase 1b dose escalation study that we presented today at ESMO GI. Despite approved therapies, targeted treatment options for gastric cancers continue to be limited. While the data are early, givastomig combination therapy demonstrates a high response rate across Claudin 18.2 and PD-L1 expression levels,' said Samuel J Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital. 'In addition, I have been pleased to observe that givastomig has a favorable overall tolerability profile with a low level of gastrointestinal side effects -- especially important for patients with gastric cancer. I look forward to participating in the ongoing givastomig clinical development program, and hope we may be able to expand the population of patients who may benefit from Claudin 18.2 directed agents.' Virtual Investor Event: Register ( here ) for the Post-ESMO GI 2025 Investor Event to be held on Tuesday, July 8th at 2:00 PM EDT. A replay of the webinar will be accessible on the Events page of the I-Mab website for 90 days. Fireside Chat Event with Lucid Capital Markets to Recap the Presentation: Tune in ( here ) for a fireside chat sponsored by Christopher Liu, PharmD, Managing Director at Lucid Capital Markets that will be accessible today at 2:00pm EDT on the Events page of the I-Mab website. A replay of the fireside chat will be available for 90 days. ESMO GI Presentation Details: A full copy of the ESMO GI presentation is available on the Publications and Presentations page of the I-Mab website here. Givastomig Phase 1b Dose Escalation Data Summary in 1L Gastric Cancers Patient Characteristics: Efficacy Results: Durability: Safety: About Givastomig Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (1L) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents. An ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data. Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company's differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents. For more information, please visit and follow us on LinkedIn and X. I-Mab Forward Looking Statements This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will', 'expects', 'believes', 'designed to', 'anticipates', 'future', 'intends', 'plans', 'potential', 'estimates', 'confident', and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline and clinical development of I-Mab's drug candidates, including givastomig; the projected advancement of the Company's portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the 'Risk Factors' section in I-Mab's annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. I-Mab Investor & Media Contacts PJ Kelleher LifeSci Advisors +1-617-430-7579 [email protected] [email protected]
Associated Press
44 minutes ago
- Associated Press
Universal Processing Celebrates Grand Opening of New Headquarters, Reinforcing Commitment to Empowering Underserved Businesses
New York, New York--(Newsfile Corp. - July 2, 2025) - Universal Processing (uP), a leading financial technology company dedicated to empowering underserved businesses across America, is looking towards the future after a star-studded grand opening of its Times Square headquarters. The theme of the night was 'Brick by Brick', a celebration of the people and partnerships that have shaped the company's journey. uP was proud to host many of the people who have been integral to the company's success, and were honored that some of New York's most well-known and influential politicians stopped by the event to make speeches. [ This image cannot be displayed. Please visit the source: ] Image 1 To view an enhanced version of this graphic, please visit: Former Governor George Pataki had this to say about uP's contributions during the COVID-19 pandemic: 'I want to thank Universal Processing, because without what you did during that terrible time, many of the businesses that New York counts on wouldn't be here today.' It was an honor for uP to be recognized by the former governor, as during the pandemic - when Asian-owned businesses across the city were hit hardest - uP stepped in as a lifeline. The company offered multilingual support, financial relief, PPE, and digital tools to help stabilize their communities. [ This image cannot be displayed. Please visit the source: ] Image 2 To view an enhanced version of this graphic, please visit: Former Governor David Patterson also stopped by to applaud uP founder and CEO, Saint Hung: 'For the leadership and all that you have done, for the efforts you waged, and your expansion of concepts that I think is bringing more business to the area and to areas around here…you've done a marvelous job and we look forward to bigger and better things.' [ This image cannot be displayed. Please visit the source: ] Image 3 To view an enhanced version of this graphic, please visit: New York State Senator Stephen Chan crafted a powerful metaphor for Hung's leadership of the company: 'Everybody here is a cog in this timepiece and everybody must be in their place and work in order for our community, our society, our city to tick,' said Mr. Chan. 'Saint is the driving force in that timepiece. He is the conductor of this symphony, and if everybody plays their part correctly, that's what is going to make it sound good. That's what is going to make it beautiful.' 'Saint Hung is committed to growing small and medium-sized businesses in New York,' said Chairman of the New York State Republican Party, Ed Cox. 'These new headquarters in New York City are about the growth of Universal Processing and about Mr. Hung's and Universal Processing's commitment to New York City. Thank you Mr. Hung.' In a surprise move, New York State Assemblymember Lester Chang awarded Universal Processing with a New York State Assembly Citation. 'I applaud you because you had the foresight, vision, and optimism to create this business,' said Assemblymember Chang. 'Writing a citation for me is easy, but earning a citation is the real work.' [ This image cannot be displayed. Please visit the source: ] Image 4 To view an enhanced version of this graphic, please visit: 'We know in New York State that it's the small businesses that are the economic engine that drive this great state,' said New York State Assemblymember Al Taylor, 'so thank you for investing, thank you for being a risk taker.' As uP continues to be recognized for its achievements in the fintech space and expand its service offerings, the company remains focused on its mission to democratize access to fintech solutions, helping more businesses move 'uP'. The new headquarters in Times Square marks a significant milestone in this journey, providing a platform for continued growth and impact. It is also particularly meaningful to founder and CEO Saint Hung, whose father - an architect - worked on Philip Johnson's Times Square Redevelopment Project in 1989. 'For me to come back here and stake my claim to Times Square, it's been an effort 36 years in the making,' said Hung. For media inquiries, event details, or partnership opportunities, please contact: Yin Yu uP PR Team [email protected] About Universal Processing Universal Processing is an award-winning fintech and payment solutions provider, specializing in serving underserved businesses and partner channels with full-service payment processing. As a certified Minority-Owned Business, uP is committed to providing transparent, secure, and scalable payment solutions with 24/7 multilingual support. Learn more at To view the source version of this press release, please visit
Associated Press
44 minutes ago
- Associated Press
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Fortrea Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the 'Class Period'), of the important August 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Fortrea securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Fortrea class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to Fortrea's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the transition service agreements ('TSAs'); (3) as a result, Fortrea's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of Fortrea's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Fortrea's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Fortrea class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
